Abstract Library

#4607 BH3-mimetic drugs elicit cell death of neuroendocrine tumours in preclinical models – An emerging therapeutic strategy for NETs

Introduction: There is an unmet clinical need to identify new, effective therapies for patients with neuroendocrine tumours (NETs). Analysis of single-cell expression data revealed that NETs express high levels of the Bcl2 family of antiapoptotic proteins. Therefore, we hypothesised that proapoptotic drugs, such as BH3-mimetics, can induce programmed cell death, i.e., apoptosis, of neuroendocrine cancer cells.

Conference:

Presenting Author: Michael I

Authors: Kulathunga N, Wang Z, Kale J, Lens A, Tsui H,

Keywords: neuroendocrine tumour, BH3-mimetics, Navitoclax, Cabozantinib, patient-derived organoids, apoptosis, 177Lu-Dotatate,

#4498 Quality of life outcome after each cycle in NET patients receiving peptide receptor radionuclide therapy (PRRT)

Introduction: Quality of Life (QoL) Questionnaire GI NET21 was developed specifically for neuroendocrine tumours (NET). A significant proportion of all patients with GEP-NETs will ultimately present with a wide variety of NET-related symptoms such as skin flushing, diarrhoea and pain as well as disease related worries that can reduce QoL. Peptide receptor radionuclide therapy (PRRT) is an established treatment in NETs and has been shown to extend survival. However, QoL data post PRRT is still somewhat limited.

Conference:

Presenting Author: Vito I

Authors: Vito I, Santillan N, Davis N, Navalkissoor S,

Keywords: Lu-177-DOTATATE, PRRT, Quality of Life,

#3199 Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): A multicentre case-control study

Introduction: Pathogenesis and risk factors of sporadic GEP-NENs are not clear and still debated.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Feola T

Authors: Feola T, Puliani G, Sesti F, Centello R, Di Vito V,

Keywords: neuroendocrine neoplasm, risk factor, obesity, diabetes mellitus, low-HDL, gastroenteropancreatic, pancreas, ileum,

#405 EUS-FNA for Pancreatic Neuroendocrine Tumors: A Single Referral Centre Experience

Introduction: Pancreatic neuroendocrine tumors (PNET) are not an uncommon finding and recent data show the importance of EUS in diagnosis of PNET.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Berretti D, Grimaldi F, Pevere S, Marino M, Angione V,

Keywords: EUS-FNA, GEP-NET,